Suppr超能文献

骨肉瘤:1975 年至 2017 年基于监测、流行病学和最终结果计划的分析。

Osteosarcoma: A Surveillance, Epidemiology, and End Results program-based analysis from 1975 to 2017.

机构信息

Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland.

Walter Reed National Military Medical Center, Bethesda, Maryland.

出版信息

Cancer. 2022 Jun 1;128(11):2107-2118. doi: 10.1002/cncr.34163. Epub 2022 Feb 28.

Abstract

BACKGROUND

Osteosarcoma is the most common primary bone malignancy. As a rare cancer, population-based studies remain small with limited information on finer demographic categories. Recent studies have reported important genetic differences based on age and ethnicity, and more detailed studies are needed to better understand potentially important osteosarcoma risk groups.

METHODS

Incidence and survival rates for 5016 patients with osteosarcoma from the Surveillance, Epidemiology, and End Results (SEER) program (1975-2017) were analyzed by age (0-9, 10-24, 25-59, and >60 years old), race/ethnicity, histologic subtype, stage, and tumor location using SEER*Stat software.

RESULTS

For cases 0 to 9 years old, incidence of primary osteosarcoma was similar between the sexes, increased significantly throughout the study period (P < .05), and the 5-year relative survival has steadily increased over time. Blacks had the highest incidence in all aged cases combined and a significant increase in incidence throughout the study period (P < .05). Overall, survival rates for all cases have remained relatively unchanged over recent decades, with worse survival observed in males, American Indian/Alaska Native cases, older patients, metastatic disease, axial tumors, and subsequent osteosarcoma cases. For cases 0 to 24 years old, the incidence of subsequent osteosarcoma increased 3-fold since the 2000s.

CONCLUSION

Important differences in osteosarcoma incidence and survival, particularly for the youngest children, ethnic minorities, and subsequent osteosarcoma, are identified. A genetic risk factor may be associated with observed ancestry-specific incidence differences and illustrates the importance of analyzing osteosarcoma by specific age groups and ethnicities to better understand their unique epidemiology and underlying biology.

LAY SUMMARY

Osteosarcoma is the most common bone cancer, but still a relatively rare disease, and previous studies have had limited information on finer demographics. Using a large database, osteosarcoma incidence and survival patterns are thoroughly evaluated and important differences, especially for the youngest children, ethnic minorities, and subsequent osteosarcoma cases, are identified.

摘要

背景

骨肉瘤是最常见的原发性骨恶性肿瘤。作为一种罕见的癌症,基于人群的研究仍然规模较小,关于更精细的人口统计学分类的信息有限。最近的研究报告了基于年龄和种族的重要遗传差异,需要更详细的研究来更好地了解潜在的重要骨肉瘤危险群体。

方法

利用 SEER*Stat 软件,对来自 Surveillance, Epidemiology, and End Results (SEER) 计划(1975-2017 年)的 5016 例骨肉瘤患者(0-9 岁、10-24 岁、25-59 岁和>60 岁)的发病率和生存率进行了年龄(0-9 岁、10-24 岁、25-59 岁和>60 岁)、种族/民族、组织学亚型、分期和肿瘤位置的分析。

结果

对于 0 至 9 岁的病例,原发性骨肉瘤的发病率在两性之间相似,在整个研究期间显著增加(P <.05),并且 5 年相对生存率随着时间的推移稳步提高。在所有年龄段的病例中,黑人的发病率最高,并且在整个研究期间发病率显著增加(P <.05)。总体而言,最近几十年来所有病例的生存率相对保持不变,男性、美洲印第安人/阿拉斯加原住民病例、年龄较大的患者、转移性疾病、轴性肿瘤和随后的骨肉瘤病例的生存率较差。对于 0 至 24 岁的病例,自 2000 年代以来,随后发生的骨肉瘤的发病率增加了 3 倍。

结论

确定了骨肉瘤发病率和生存率的重要差异,特别是对于年龄最小的儿童、少数民族和随后的骨肉瘤。遗传风险因素可能与观察到的特定种族的发病率差异有关,这说明了按特定年龄组和种族分析骨肉瘤以更好地了解其独特的流行病学和潜在生物学的重要性。

患者人群

骨肉瘤是最常见的骨癌,但仍是一种相对罕见的疾病,之前的研究对更精细的人口统计学信息的了解有限。

研究方法

使用大型数据库,全面评估骨肉瘤的发病率和生存率模式,并确定重要差异,特别是对于年龄最小的儿童、少数民族和随后的骨肉瘤病例。

研究结果

骨肉瘤是最常见的原发性骨恶性肿瘤,但仍是一种相对罕见的疾病,之前的研究对更精细的人口统计学信息的了解有限。

研究结论

使用大型数据库,全面评估骨肉瘤的发病率和生存率模式,并确定重要差异,特别是对于年龄最小的儿童、少数民族和随后的骨肉瘤病例。

相似文献

1
Osteosarcoma: A Surveillance, Epidemiology, and End Results program-based analysis from 1975 to 2017.
Cancer. 2022 Jun 1;128(11):2107-2118. doi: 10.1002/cncr.34163. Epub 2022 Feb 28.
4
Increased survival of patients aged 0-29 years with osteosarcoma: A period analysis, 1984-2013.
Cancer Med. 2018 Aug;7(8):3652-3661. doi: 10.1002/cam4.1659. Epub 2018 Jul 10.
5
The Role of Sociodemographics in Pediatric, Adolescent and Young Adult Osteosarcoma: A Population Based Study.
J Pediatr Surg. 2025 Apr;60(4):162202. doi: 10.1016/j.jpedsurg.2025.162202. Epub 2025 Jan 29.
6
Secondary malignant neoplasms among children, adolescents, and young adults with osteosarcoma.
Cancer. 2014 Dec 15;120(24):3987-93. doi: 10.1002/cncr.28936. Epub 2014 Aug 12.
7
Derivation and validation of risk groups in patients with osteosarcoma utilizing regression tree analysis.
Pediatr Blood Cancer. 2021 Mar;68(3):e28834. doi: 10.1002/pbc.28834. Epub 2020 Nov 30.
8
Childhood cancer among Alaska Natives.
Pediatrics. 2003 Nov;112(5):e396. doi: 10.1542/peds.112.5.e396.
10
Demographic determinants of survival in osteosarcoma.
Ann Acad Med Singap. 2012 Sep;41(9):390-9.

引用本文的文献

1
Linking Environmental Hazards to Osteosarcoma Development: A Comprehensive Review.
Cancer Manag Res. 2025 Aug 21;17:1725-1739. doi: 10.2147/CMAR.S542371. eCollection 2025.
2
Sulfasalazine induces ferroptosis in osteosarcomas by regulating Nrf2/SLC7A11/GPX4 signaling axis.
Sci Rep. 2025 Aug 18;15(1):30197. doi: 10.1038/s41598-025-13324-5.
3
Supporting Participant Engagement in Cancer Genomics Research in Rare Cancers: A Qualitative Study of Patients, Caregivers, and Advocates.
Cancer Control. 2025 Jan-Dec;32:10732748251364041. doi: 10.1177/10732748251364041. Epub 2025 Jul 28.
5
Correlation Between MRI Characteristic of Osteosarcoma with 2-Year Survival Outcomes.
Diagnostics (Basel). 2025 Jul 3;15(13):1707. doi: 10.3390/diagnostics15131707.
6
Comprehensive multi-omics analysis reveals the prognostic and immune regulatory characteristics of the PTPN family in osteosarcoma.
PLoS One. 2025 Jun 26;20(6):e0326872. doi: 10.1371/journal.pone.0326872. eCollection 2025.
7
Doxycycline Enhances Anticancer Activity of Zoledronic Acid via Inducing ROS and Autophagy in Osteosarcoma Cell Lines.
Int J Med Sci. 2025 May 9;22(11):2560-2569. doi: 10.7150/ijms.108086. eCollection 2025.

本文引用的文献

1
Pathogenesis and Current Treatment of Osteosarcoma: Perspectives for Future Therapies.
J Clin Med. 2021 Mar 12;10(6):1182. doi: 10.3390/jcm10061182.
2
Osteosarcoma of the jaws: An overview of the pathophysiological mechanisms.
Crit Rev Oncol Hematol. 2020 Dec;156:103126. doi: 10.1016/j.critrevonc.2020.103126. Epub 2020 Oct 10.
3
Epidemiology and Risk Factors of Osteosarcoma.
Cancer Invest. 2020 May;38(5):259-269. doi: 10.1080/07357907.2020.1768401. Epub 2020 Jun 1.
4
Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in Patients With Osteosarcoma.
JAMA Oncol. 2020 May 1;6(5):724-734. doi: 10.1001/jamaoncol.2020.0197.
6
Characteristics and Prognostic Factors of Patients With Osteosarcoma Older Than 60 Years From the SEER Database.
Cancer Control. 2019 Jan-Dec;26(1):1073274819888893. doi: 10.1177/1073274819888893.
7
Predictors of the Survival of Primary and Secondary Older Osteosarcoma Patients.
J Cancer. 2019 Aug 7;10(19):4614-4622. doi: 10.7150/jca.32627. eCollection 2019.
9
Secondary osteosarcoma in patients previously treated for childhood cancer: Three case reports.
Mol Clin Oncol. 2019 Jan;10(1):153-158. doi: 10.3892/mco.2018.1752. Epub 2018 Oct 26.
10

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验